Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Industry News

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

June 01, 2020

News Industry News

Boston Scientific Initiates Trial Comparing Left Atrial Appendage Closure to Direct Oral Anticoagulants for Stroke Risk Reduction Post-AFib Ablation

May 22, 2019

News Industry News

RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa®

August 28, 2017

News Industry News

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

November 29, 2015

News Industry News

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

September 09, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Industry News

Efficacy and Safety Profile of Pradaxa® (dabigatran etexilate) Repeatedly Confirmed

July 23, 2014

News Industry News

New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients

May 07, 2014

News Industry News

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

May 11, 2012

Advertisement

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

Boston Scientific Initiates Trial Comparing Left Atrial Appendage Closure to Direct Oral Anticoagulants for Stroke Risk Reduction Post-AFib Ablation

RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa®

Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)

Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) in Nonvalvular Atrial Fibrillation Patients with a Recent ACS or Undrgoing PCI

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

Efficacy and Safety Profile of Pradaxa® (dabigatran etexilate) Repeatedly Confirmed

New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients

Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content